📊 UNCY Key Takeaways
Is Unicycive Therapeutics, Inc. (UNCY) a Good Investment?
Unicycive is a pre-commercial biotech burning $31.3M annually against minimal revenue of $675K, leaving less than 12 months of cash runway at current burn rates. Declining revenue (-29% YoY), massive operating losses (-4,373% margin), and unsustainable cash burn present acute liquidity risk despite a clean balance sheet.
Why Buy Unicycive Therapeutics, Inc. Stock? UNCY Key Strengths
- Zero long-term debt with clean capital structure
- Strong liquidity position with 2.59x current ratio and $29.2M cash
- Improved EPS YoY (-$1.67 vs prior -$5.68) suggests operational improvement trajectory
UNCY Stock Risks: Unicycive Therapeutics, Inc. Investment Risks
- Critical cash runway: $31.3M annual burn against $29.2M cash (less than 12 months)
- Collapsing revenue base: $675K with -29% YoY decline indicates failed commercialization or lost contracts
- Extreme operating losses relative to revenue scale: -$29.5M operating loss on minimal top line unsustainable without immediate inflection or capital raise
- No insider buying activity signals limited confidence from management
Key Metrics to Watch
- Cash position and runway - critical near-term solvency indicator
- Revenue trends and pipeline advancement - requires demonstrable growth to justify burn rate
- Debt or equity financing announcements - likely necessary for survival beyond Q3 2026
Unicycive Therapeutics, Inc. (UNCY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.59x current ratio provides a solid financial cushion.
UNCY Profit Margin, ROE & Profitability Analysis
UNCY vs Healthcare Sector: How Unicycive Therapeutics, Inc. Compares
How Unicycive Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Unicycive Therapeutics, Inc. Stock Overvalued? UNCY Valuation Analysis 2026
Based on fundamental analysis, Unicycive Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Unicycive Therapeutics, Inc. Balance Sheet: UNCY Debt, Cash & Liquidity
UNCY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Unicycive Therapeutics, Inc.'s revenue has declined by 29% over the 5-year period, indicating business contraction. The most recent EPS of $-5.65 indicates the company is currently unprofitable.
UNCY Revenue Growth, EPS Growth & YoY Performance
UNCY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $675.0K | -$3.8M | $-0.05 |
| Q2 2024 | $675.0K | -$3.8M | $-0.15 |
| Q1 2024 | $675.0K | -$14.6M | $-0.61 |
| Q3 2023 | $675.0K | -$3.5M | $-0.13 |
| Q2 2023 | $675.0K | -$3.5M | $-0.24 |
| Q1 2023 | $675.0K | -$3.5M | $-0.24 |
| Q3 2022 | $951.0K | -$964.0K | $-0.37 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Unicycive Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
UNCY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Unicycive Therapeutics, Inc. (CIK: 0001766140)
📋 Recent SEC Filings
❓ Frequently Asked Questions about UNCY
What is the AI rating for UNCY?
Unicycive Therapeutics, Inc. (UNCY) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are UNCY's key strengths?
Claude: Zero long-term debt with clean capital structure. Strong liquidity position with 2.59x current ratio and $29.2M cash.
What are the risks of investing in UNCY?
Claude: Critical cash runway: $31.3M annual burn against $29.2M cash (less than 12 months). Collapsing revenue base: $675K with -29% YoY decline indicates failed commercialization or lost contracts.
What is UNCY's revenue and growth?
Unicycive Therapeutics, Inc. reported revenue of $675.0K.
Does UNCY pay dividends?
Unicycive Therapeutics, Inc. pays dividends, with $1.1M distributed to shareholders in the trailing twelve months.
Where can I find UNCY SEC filings?
Official SEC filings for Unicycive Therapeutics, Inc. (CIK: 0001766140) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is UNCY's EPS?
Unicycive Therapeutics, Inc. has a diluted EPS of $-1.67.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is UNCY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Unicycive Therapeutics, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is UNCY stock overvalued or undervalued?
Valuation metrics for UNCY: ROE of -87.9% (sector avg: 15%), net margin of -3,934.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy UNCY stock in 2026?
Our dual AI analysis gives Unicycive Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is UNCY's free cash flow?
Unicycive Therapeutics, Inc.'s operating cash flow is $-31.3M, with capital expenditures of $24.0K. FCF margin is -4,643.1%.
How does UNCY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,934.1% (avg: 12%), ROE -87.9% (avg: 15%), current ratio 2.59 (avg: 2).